Jump to content

BMB-101

Add links
From Wikipedia, the free encyclopedia

BMB-101
Clinical data
Other namesBMB101
Routes of
administration		Oral[1]
Drug classSerotonin 5-HT2C receptor agonist[1]

BMB-101 is a serotonin 5-HT2C receptor agonist which is under development for the treatment of absence epilepsy, Pitt-Hopkins syndrome, Dravet syndrome, binge-eating disorder, Lennox-Gastaut syndrome, and opioid-related disorders.[1][2][3][4][5] It is taken by mouth.[1]

The drug acts as a highly selective biased agonist of the serotonin 5-HT2C receptor.[1][6][3][5] It has greater that 100-fold selectivity for the serotonin 5-HT2C receptor over other serotonin receptors, including the serotonin 5-HT2A and 5-HT2B receptors.[3][5] BMB-101 shows functional selectivity at the serotonin 5-HT2C receptor for activation of Gq signaling with minimal β-arrestin recruitment.[6][3][5] This in turn appears to minimize receptor desensitization and development of tolerance.[6][3] Due to its much greater selectivity for the serotonin 5-HT2C receptor, BMB-101 is not expected to possess the psychedelic effects or cardiotoxicity that have been associated with existing drugs like fenfluramine and lorcaserin at therapeutic or supratherapeutic doses.[3][4][5] In accordance with its mechanism of action, BMB-101 produces anticonvulsant effects in animals.[4]

BMB-101 is under development by Bright Minds Biosciences.[1][2] As of October 2023, it is in phase 2 clinical trials for absence epilepsy and Pitt-Hopkins syndrome, phase 1 clinical trials for Dravet syndrome, and is in preclinical research for binge-eating disorder, Lennox-Gastaut syndrome, and opioid-related disorders.[1][2] The chemical structure of BMB-101 does not yet appear to have been disclosed.[1][2]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g h "BMB 101". AdisInsight. 23 October 2024. Retrieved 30 October 2024.
  2. ^ a b c d "Delving into the Latest Updates on BMB-101 with Synapse". Synapse. 29 October 2024. Retrieved 30 October 2024.
  3. ^ a b c d e f Vasilkevich A, Duan J, Smith M, McCorvy JD, Pedersen J (May 2024). BMB-101: A selective 5-HT2C agonist for the treatment of rare epilepsies (PDF). Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII), Madrid, Spain 5 - 8 May 2024.
  4. ^ a b c Vasilkevich A, Lovera A, Duan J, Smith MA, McCorvy J, Pedersen JT (October 2024). Selective 5-HT2C Agonists for the Treatment of Rare Epileptic Disorders (PDF). Society for Neuroscience 2024 Annual Meeting (Chicago), Satellite NIH Forum, October 5-9.
  5. ^ a b c d e "Bright Minds Investor Deck" (PDF). Bright Minds Biosciences Inc. September 2024.
  6. ^ a b c "Bright Minds Biosciences Launches Phase 2 Trial of BMB-101 for Epilepsy". Synapse. 14 September 2024. Retrieved 30 October 2024.
[edit]
Retrieved from "https://wiki.riteme.site/w/index.php?title=BMB-101&oldid=1258512947"